96.90+0.02 (+0.02%)
At close: 4:00PM EST
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 96.88 |
| Open | 96.94 |
| Bid | 95.91 x 900 |
| Ask | 97.52 x 900 |
| Day's Range | 96.55 - 97.52 |
| 52 Week Range | 69.18 - 99.84 |
| Volume | 2,531,829 |
| Avg. Volume | 1,946,512 |
| Market Cap | 220.672B |
| Beta (5Y Monthly) | 0.54 |
| PE Ratio (TTM) | 31.39 |
| EPS (TTM) | 3.09 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.09 (3.19%) |
| Ex-Dividend Date | Mar 03, 2020 |
| 1y Target Est | 107.00 |
- Zacks
Incyte's (INCY) BLA for Cancer Drug Accepted for Priority Review
Incyte's (INCY) application for pipeline candidate, retifanlimab, for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) gets Priority Review.
- Zacks
Merck's (MRK) Heart Failure Drug Vericiguat Gets FDA Nod
Merck (MRK)/Bayer's (BAYRY) vericiguat gets FDA approval for symptomatic chronic heart failure and reduced ejection fraction
- Zacks
The Zacks Analyst Blog Highlights: Novartis, QUALCOMM, Accenture, MetLife and Electronic Arts
The Zacks Analyst Blog Highlights: Novartis, QUALCOMM, Accenture, MetLife and Electronic Arts
© 2021 Verizon Media. All rights reserved.
